Integrating ultrasound and serum indicators for evaluating outcomes of targeted immunotherapy in advanced liver cancer

Table 3 Prediction performance of different models in different groups

	Model	AUC	AUC 95%CI	Sensitivity	Specificity	PPV	NPV	Accuracy
Internal training cohort	TIPM	0.895	0.845-0.945	0.65	0.961	0.866	0.876	0.874
	TNM	0.541	0.460-0.623	0.672	0.721	0.735	0.655	0.624
	BCLC	0.446	0.364-0.527	0.685	0.734	0.724	0.751	0.675
	CNLC	0.500	0.419-0.582	0.648	0.654	0.812	0.802	0.741
	HKLC	0.526	0.444-0.608	0.724	0.801	0.751	0.754	0.657
	CRAFITY	0.571	0.490-0.652	0.85	0.721	0.654	0.793	0.751
Internal validation cohort	TIPM	0.907	0.835-0.979	0.636	0.980	0.875	0.925	0.919
	TNM	0.515	0.375-0.624	0.624	0.655	0.561	0.688	0.675
	BCLC	0.614	0.492-0.735	0.715	0.457	0.558	0.724	0.742
	CNLC	0.405	0.283-0.527	0.537	0.621	0.597	0.739	0.567
	HKLC	0.432	0.308-0.555	0.522	0.439	0.621	0.751	0.744
	CRAFITY	0.524	0.400-0.649	0.727	0.702	0.701	0.755	0.685
External validation cohort	TIPM	0.899	0.840-0.957	0.642	0.972	0.901	0.876	0.881
	TNM	0.518	0.420-0.615	0.577	0.715	0.544	0.674	0.655
	BCLC	0.474	0.376-0.571	0.622	0.702	0.658	0.587	0.724
	CNLC	0.584	0.488-0.680	0.478	0.658	0.728	0.653	0.726
	HKLC	0.505	0.408-0.603	0.685	0.653	0.648	0.724	0.658
	CRAFITY	0.546	0.449-0.644	0.892	0.654	0.722	0.769	0.685

AUC: Area under the curve; CI: Confidence interval; PPV: Positive predict value; NPV: Negative predict value; TIPM: Target Immunotherapy Predictive Model; TNM: Tumor-node-metastasis; BCLC: Barcelona Clinic Liver Cancer; CNLC: China Liver Cancer; HKLC: Hong Kong Liver Cancer; CRAFITY: C-reactive protein and alpha-fetoprotein in immunotherapy.